What is Aimovig
Aimovig is a prescription medicine that helps prevent migraine in adults. It is indicated for patients who have at least four migraine days per month.
Aimovig is the first monoclonal antibody treatment specifically developed to block the preventive treatment of migraine in adults by targeting CGRP receptors.
Aimovig is available as one subcutaneous injection, once a month, using either a pre-filled syringe or a pre-filled pen. It comes in two doses: 70 mg and 140 mg. The recommended dose is 70 mg every four weeks, but the dose may be increased 140 mg dose depending on the effectiveness of the lower dose.1
 |  |
For some people, Aimovig can cut the number of monthly migraine days in half or more.2
In clinical studies, some people experienced a 50% or greater reduction in monthly migraine days. In a three-month clinical trial, people with chronic migraine had 6–7 fewer monthly migraine days on average. For those with episodic migraine, tested over six months, Aimovig helped reduce monthly migraine days by 3–4 on average.
FDA approval of Aimovig marked a significant step forward in migraine prevention. However, it should not be used by patients who are allergic or hypersensitive to erenumab-aooe or any of its ingredients.
How does it work?
Aimovig is specifically designed to help prevent migraines. It works by selectively targeting and blocking the calcitonin gene-related peptide receptors (CGRP-R), which are believed to play a key role in triggering migraines. By preventing CGRP from binding to its receptor, Aimovig helps interrupt the migraine pathway. It is currently the only preventive treatment of migraine in adults that functions in this unique way using a monoclonal antibody.
Method of administration
Aimovig is for subcutaneous use. The injection is to be administered into the outer area of the upper arm by a suitably trained pharmacist. Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red or hard.1
Aimovig comes in either a pre-filled syringe or a pre-filled pen. Each pre-filled syringe or pen is designed for single use. The solution should be stored at room temperature and inspected before use to ensure it’s clear to opalescent, colourless to light yellow, and free from particles.
The package leaflet contains comprehensive instructions for administration.
Side effects and warnings
As with all medications, Aimovig may cause common side effects. These include injection site reactions, constipation, and allergic reactions. In rare cases, constipation with serious complications may occur. Patients should report any persistent or concerning symptoms to their pharmacist or GP.
Supply
Following a consultation with our pharmacist we can review your current symptoms and history to see if this is suitable for you. No appointment is necessary and the service is available in all our pharmacies.
Prescribing information
Please visit the EMC website for the Aimovig prescribing information.
Service details
Price: The cost for treatment following a consultation is £500 which covers a one month supply.
Frequency: When required…
References
- Novartis Pharmaceuticals UK Ltd, Summary of product characteristics, Aimovig 140 mg solution for injection in pre-filled pen, Updated 10 September 2019 [Accessed 04 November 2019], available at: https://www.medicines.org.uk/emc/product/10297/smpc
- Aimovig.com, what is Aimovig, Accessed 04 November 2019, available at: https://www.aimovig.com/what-is-aimovig
